Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.66 |
| ▸ | ABL1 | P00519 | 3/20 | 0.66 |
| ▸ | INSR | P06213 | 3/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.66 |
| ▸ | CDK2 | P24941 | 3/20 | 0.66 |
| ▸ | PLK1 | P53350 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334087 | 0.96 | EGFR (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL4338866 | 0.94 | EGFR (0.70) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL4787084 | 0.92 | HDAC1 (0.76) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL4739391 | 0.92 | HDAC1 (0.76) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL4337630 | 0.88 | HDAC3 (0.83) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL4740256 | 0.88 | EGFR (0.74) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL4334092 | 0.85 | EGFR (0.77) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL2699813 | 0.84 | EGFR (0.70) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL4348156 | 0.83 | ERBB2 (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL15766158 | 0.83 | EGFR (0.79) | EGFRERBB2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8604044-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2061772-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061773-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | EGFR 2358/4885ERBB2 2794/4885HDAC3 7/4885 |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC5, ERBB4 | EGFR 1/4885ERBB2 7/4885HDAC3 17/4885 |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | HDAC1, HDAC8, EGFR | EGFR 3/4885ERBB2 9/4885HDAC3 12/4885 |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, ERBB4, HDAC5 | EGFR 1/4885ERBB2 7/4885HDAC3 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.